

UNITED STATE EPARTMENT OF COMMERCE United States Patent and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		TTORNEY DOCKET NO.
09/473,71	3 12/29/99	THATCHER	G	1995-033-120
-		7	E	XAMINER
,,	· ,,, + ga, s, ppp	HM12/0410	Y	170 0
STEPHEN J SCRIBNER			D SOUZA.A	
PARTEQ INNOVATIONS			ART UNIT	PAPER NUMBER
QUEENS UN	IIVERSITY	·		
KINGSTON	ON K7L 3N6		1626	1
CANADA	mild by the milder	ATO MATI		,
СНИНГН		AIR MAIL	DATE MAILED:	
				04/10/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

	Application No.	Applicant(s)
3	09/473,713	THATCHER ET AL.
Offic Action Summary	Examiner	Art Unit
	Andrea M D'Souza	1626
	cation appears on the cover sheet with	the correspondence address
Period for Reply	OD DEDLY IS SET TO EVDIDE 4 MC	MITH(S) EDOM
A SHORTENED STATUTORY PERIOD F THE MAILING DATE OF THIS COMMUN - Extensions of time may be available under the provisions after SIX (6) MONTHS from the mailing date of this comm - If the period for reply specified above is less than thirty (3 - If NO period for reply is specified above, the maximum si - Failure to reply within the set or extended period for reply - Any reply received by the Office later than three months a earned patent term adjustment. See 37 CFR 1.704(b). Status	ICATION. s of 37 CFR 1.136 (a). In no event, however, may a repunication. 30) days, a reply within the statutory minimum of thirty attutory period will apply and will expire SIX (6) MONTER AUGUST AU	ply be timely filed (30) days will be considered timely. HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).
	iled on Supplemental IDS filed 5/9/200	<u>00</u> .
2a) ☐ This action is FINAL.	2b) This action is non-final.	
3) Since this application is in conditio	n for allowance except for formal matte ctice under <i>Ex parte Quayle</i> , 1935 C.D	ers, prosecution as to the merits is . 11, 453 O.G. 213.
Disposition of Claims		
4)⊠ Claim(s) 1-32 is/are pending in the	application.	
4a) Of the above claim(s) is/a	re withdrawn from consideration.	·
5) Claim(s) is/are allowed.	•	
6) Claim(s) is/are rejected.	•	
7) Claim(s) is/are objected to.		
8) Claims 1-32 are subject to restrict	on and/or election requirement.	
Application Papers		
9) The specification is objected to by t	he Examiner	
10) The drawing(s) filed on is/are	e objected to by the Examiner.	•
11) The proposed drawing correction fil	ed on is: a) ☐ approved b) ☐	disapproved.
12) The oath or declaration is objected	to by the Examiner.	
Priority under 35 U.S.C. § 119		
13) Acknowledgment is made of a clain	n for foreign priority under 35 U.S.C. §	119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority	documents have been received.	
2. Certified copies of the priority	documents have been received in Ap	plication No
	of the priority documents have been renational Bureau (PCT Rule 17.2(a)).	
See the attached detailed Office action14) Acknowledgement is made of a claim		
14) Acknowledgement is made of a clai	m for domestic priority under 33 0.3.0	g 110(c).
4.	,	
Attachment(s)		
 15) Notice of References Cited (PTO-892) 16) Notice of Draftsperson's Patent Drawing Review 17) Information Disclosure Statement(s) (PTO-1449) 	(PTO-948) 19) Notice of I	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)

Application/Control Number: 09/473,713

Art Unit: 1626

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-10, 21, 23, 25, and 27 drawn to method for treating pain.
- II. Claims 11-20, drawn to methods of providing sedation.
- III. Claim 29, drawn to various products.
- IV. Claim 30 and 32, drawn to various products.
- V. Claim 31 and 32, drawn to various products.

The inventions are distinct, each from the other because of the following reasons:

1. The above groups are identified as general areas. Accordingly, as groups, they are independent or distinct as the methods of use of group I and group II would be capable of use by more than one process, as seen in claim 1or claim 11. The various products of claim 29, 30, and 31 would be capable of producing by more than one process, as seen in example 29, page 67; example 21, page 63; and example 18, page 62. These products would also be capable of more than one use, e.g. treating pain and sedation, and as such separate search considerations are involved, which would impose a burden if unrestricted.

Application/Control Number: 09/473,713

Art Unit: 1626

2. The above groups themselves are inclusive of patentably distinct subject matter.

Accordingly, along with the election of one of the above groups, the following action is also taken.

Claim 1, 11, 29, 30, and 31 are generic to a plurality of disclosed patentably distinct species comprising, for example, the compounds of (I) Examples 28 and 29, pages 66 and 67; Examples 26 and 27, page 66; Examples 11 and 20, pages 59 and 63, etc. and (2) a method of treating a disease using the compounds as in Example 5 and Example 30, etc. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

4. Upon the election of a single disclosed species (e.g. Example, page number and structural depiction), a generic concept, inclusive of the elected species, will be identified by the Examiner for examination. Moreover, whatever specific compound is ultimately elected, applicants are required to list all claims readable thereon.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Andrea M. D'souza, whose telephone number is (703) 305-0811. The examiner can normally be reached on Monday-Thursday from 8:30 AM - 7:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Joseph K. McKane, can be reached at (703) 308-4537. The Unofficial fax phone

Application/Control Number: 09/473,713

Art Unit: 1626

number for this Group is (703) 308-7921. The Official fax phone numbers for this Group are (703) 308-4556 or 305-3592.

Page 4

When filing a FAX in Technology Center 1600, please indicate in the Header (upper right) "Official" for papers that are to be entered into the file, and "Unofficial" for draft documents and other communications with the PTO that are not for entry into the file of the application. This will expedite processing of your papers.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [johann.richter@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (703) 308-1234

Andrea M. D'souza April 6, 2001 Robert Ramsuer

Primary Patent Examiner

Art Unit 1626

Technology Center 1